Titre : Neurofibromine-1

Neurofibromine-1 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Network Meta-Analysis
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Neurofibromine-1 : Questions médicales les plus fréquentes", "headline": "Neurofibromine-1 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Neurofibromine-1 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-16", "dateModified": "2025-03-11", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Neurofibromine-1" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéines suppresseurs de tumeurs", "url": "https://questionsmedicales.fr/mesh/D025521", "about": { "@type": "MedicalCondition", "name": "Protéines suppresseurs de tumeurs", "code": { "@type": "MedicalCode", "code": "D025521", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.624.776" } } }, "about": { "@type": "MedicalCondition", "name": "Neurofibromine-1", "alternateName": "Neurofibromin 1", "code": { "@type": "MedicalCode", "code": "D025542", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Valentina Botero", "url": "https://questionsmedicales.fr/author/Valentina%20Botero", "affiliation": { "@type": "Organization", "name": "Department of Neuroscience and Pharmacology, University of Iowa Carver College of Medicine, Iowa City, Iowa, United States of America." } }, { "@type": "Person", "name": "Hélène Bénédetti", "url": "https://questionsmedicales.fr/author/H%C3%A9l%C3%A8ne%20B%C3%A9n%C3%A9detti", "affiliation": { "@type": "Organization", "name": "Centre de Biophysique Moléculaire, CNRS, UPR 4301, University of Orléans and INSERM, CEDEX 2, 45071 Orléans, France." } }, { "@type": "Person", "name": "Matthew Drew", "url": "https://questionsmedicales.fr/author/Matthew%20Drew", "affiliation": { "@type": "Organization", "name": "NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21701, USA." } }, { "@type": "Person", "name": "Dominic Esposito", "url": "https://questionsmedicales.fr/author/Dominic%20Esposito", "affiliation": { "@type": "Organization", "name": "NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21701, USA." } }, { "@type": "Person", "name": "Dwight V Nissley", "url": "https://questionsmedicales.fr/author/Dwight%20V%20Nissley", "affiliation": { "@type": "Organization", "name": "NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21701, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Prognostic significance of C-reactive protein in patients with cervical cancer: a meta-analysis.", "datePublished": "2023-09-01", "url": "https://questionsmedicales.fr/article/37731642", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fonc.2023.1232409" } }, { "@type": "ScholarlyArticle", "name": "Polymorphisms in FSHR modulating susceptibility to polycystic ovary syndrome: an updated meta-analysis.", "datePublished": "2023-09-01", "url": "https://questionsmedicales.fr/article/37653412", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s13048-023-01238-7" } }, { "@type": "ScholarlyArticle", "name": "The prevalence of vancomycin-resistant Staphylococcus aureus in Ethiopia: a systematic review and meta-analysis.", "datePublished": "2023-08-30", "url": "https://questionsmedicales.fr/article/37649060", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s13756-023-01291-3" } }, { "@type": "ScholarlyArticle", "name": "Safety and Effectiveness of Sclerotherapy for Nonparasitic Splenic Cysts: A Systematic Review and Meta-Analysis.", "datePublished": "2023-08-29", "url": "https://questionsmedicales.fr/article/37652298", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jvir.2023.08.033" } }, { "@type": "ScholarlyArticle", "name": "Prognostic significance of STING expression in solid tumor: a systematic review and meta-analysis.", "datePublished": "2023-08-29", "url": "https://questionsmedicales.fr/article/37711192", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fonc.2023.1244962" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines tumorales", "item": "https://questionsmedicales.fr/mesh/D009363" }, { "@type": "ListItem", "position": 5, "name": "Protéines suppresseurs de tumeurs", "item": "https://questionsmedicales.fr/mesh/D025521" }, { "@type": "ListItem", "position": 6, "name": "Neurofibromine-1", "item": "https://questionsmedicales.fr/mesh/D025542" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Neurofibromine-1 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Neurofibromine-1", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-05", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Neurofibromine-1", "description": "Comment diagnostiquer la neurofibromatose de type 1 ?\nQuels tests génétiques sont utilisés ?\nQuels signes cliniques sont observés ?\nLes IRM sont-elles utiles pour le diagnostic ?\nQuel rôle joue l'historique familial ?", "url": "https://questionsmedicales.fr/mesh/D025542?mesh_terms=Network+Meta-Analysis&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Neurofibromine-1", "description": "Quels sont les symptômes courants de la neurofibromatose ?\nLes troubles cognitifs sont-ils fréquents ?\nY a-t-il des complications oculaires ?\nComment les douleurs sont-elles ressenties ?\nLes symptômes varient-ils d'une personne à l'autre ?", "url": "https://questionsmedicales.fr/mesh/D025542?mesh_terms=Network+Meta-Analysis&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Neurofibromine-1", "description": "Peut-on prévenir la neurofibromatose de type 1 ?\nLe dépistage précoce est-il recommandé ?\nY a-t-il des conseils pour les familles à risque ?\nLes tests génétiques sont-ils utiles pour la prévention ?\nComment sensibiliser à la maladie ?", "url": "https://questionsmedicales.fr/mesh/D025542?mesh_terms=Network+Meta-Analysis&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Neurofibromine-1", "description": "Quels traitements sont disponibles pour la neurofibromatose ?\nLa chirurgie est-elle toujours nécessaire ?\nDes médicaments sont-ils prescrits ?\nY a-t-il des thérapies ciblées ?\nComment se déroule le suivi médical ?", "url": "https://questionsmedicales.fr/mesh/D025542?mesh_terms=Network+Meta-Analysis&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Neurofibromine-1", "description": "Quelles sont les complications possibles ?\nLes complications peuvent-elles affecter la qualité de vie ?\nY a-t-il des risques de cancer associés ?\nComment gérer les complications ?\nLes complications sont-elles prévisibles ?", "url": "https://questionsmedicales.fr/mesh/D025542?mesh_terms=Network+Meta-Analysis&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Neurofibromine-1", "description": "Quels sont les facteurs de risque de la neurofibromatose ?\nLa neurofibromatose est-elle héréditaire ?\nLes facteurs environnementaux jouent-ils un rôle ?\nLes mutations génétiques sont-elles fréquentes ?\nY a-t-il des groupes à risque particulier ?", "url": "https://questionsmedicales.fr/mesh/D025542?mesh_terms=Network+Meta-Analysis&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer la neurofibromatose de type 1 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'examen clinique et l'identification de critères spécifiques." } }, { "@type": "Question", "name": "Quels tests génétiques sont utilisés ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques peuvent identifier des mutations dans le gène NF1." } }, { "@type": "Question", "name": "Quels signes cliniques sont observés ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent des neurofibromes, des taches café au lait et des frecklings." } }, { "@type": "Question", "name": "Les IRM sont-elles utiles pour le diagnostic ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les IRM peuvent détecter des tumeurs et des anomalies nerveuses." } }, { "@type": "Question", "name": "Quel rôle joue l'historique familial ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Un historique familial de neurofibromatose peut renforcer le diagnostic." } }, { "@type": "Question", "name": "Quels sont les symptômes courants de la neurofibromatose ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des neurofibromes, des taches cutanées et des douleurs." } }, { "@type": "Question", "name": "Les troubles cognitifs sont-ils fréquents ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles d'apprentissage et des difficultés cognitives peuvent survenir." } }, { "@type": "Question", "name": "Y a-t-il des complications oculaires ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des tumeurs de la rétine peuvent se produire." } }, { "@type": "Question", "name": "Comment les douleurs sont-elles ressenties ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les douleurs peuvent être localisées autour des neurofibromes ou diffuses." } }, { "@type": "Question", "name": "Les symptômes varient-ils d'une personne à l'autre ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'expression des symptômes peut varier considérablement entre les individus." } }, { "@type": "Question", "name": "Peut-on prévenir la neurofibromatose de type 1 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de méthode de prévention pour cette maladie génétique." } }, { "@type": "Question", "name": "Le dépistage précoce est-il recommandé ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Le dépistage précoce peut aider à identifier les symptômes et à initier le suivi." } }, { "@type": "Question", "name": "Y a-t-il des conseils pour les familles à risque ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les familles à risque devraient consulter un généticien pour des conseils adaptés." } }, { "@type": "Question", "name": "Les tests génétiques sont-ils utiles pour la prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests génétiques peuvent aider à identifier les porteurs de mutations." } }, { "@type": "Question", "name": "Comment sensibiliser à la maladie ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "La sensibilisation peut se faire par des campagnes d'information et des ressources éducatives." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour la neurofibromatose ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent la surveillance, la chirurgie et la gestion des symptômes." } }, { "@type": "Question", "name": "La chirurgie est-elle toujours nécessaire ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Non, la chirurgie est réservée aux cas où les neurofibromes causent des problèmes." } }, { "@type": "Question", "name": "Des médicaments sont-ils prescrits ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments peuvent être utilisés pour gérer la douleur et d'autres symptômes." } }, { "@type": "Question", "name": "Y a-t-il des thérapies ciblées ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des recherches sont en cours sur des thérapies ciblées pour la neurofibromatose." } }, { "@type": "Question", "name": "Comment se déroule le suivi médical ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Le suivi médical régulier est essentiel pour surveiller l'évolution de la maladie." } }, { "@type": "Question", "name": "Quelles sont les complications possibles ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des tumeurs malignes, des problèmes neurologiques et des douleurs." } }, { "@type": "Question", "name": "Les complications peuvent-elles affecter la qualité de vie ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent significativement impacter la qualité de vie des patients." } }, { "@type": "Question", "name": "Y a-t-il des risques de cancer associés ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients ont un risque accru de développer certains types de cancer." } }, { "@type": "Question", "name": "Comment gérer les complications ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "La gestion des complications nécessite une approche multidisciplinaire et un suivi régulier." } }, { "@type": "Question", "name": "Les complications sont-elles prévisibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être prévisibles, mais leur apparition varie selon les individus." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque de la neurofibromatose ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux et des mutations génétiques spécifiques." } }, { "@type": "Question", "name": "La neurofibromatose est-elle héréditaire ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la neurofibromatose de type 1 est généralement héréditaire et autosomique dominante." } }, { "@type": "Question", "name": "Les facteurs environnementaux jouent-ils un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, les facteurs environnementaux ne sont pas clairement établis comme des risques." } }, { "@type": "Question", "name": "Les mutations génétiques sont-elles fréquentes ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les mutations dans le gène NF1 sont fréquentes chez les personnes atteintes." } }, { "@type": "Question", "name": "Y a-t-il des groupes à risque particulier ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Les individus ayant des antécédents familiaux sont à risque accru de développer la maladie." } } ] } ] }

Sources (10000 au total)

Prognostic significance of C-reactive protein in patients with cervical cancer: a meta-analysis.

Numerous studies have investigated the significance of pretreatment C-reactive protein (CRP) levels for determining the prognosis of cervical cancer (CC). The results of these studies, however, have b... We searched the following databases from their inception until April 18, 2023: PubMed; Web of Science; Embase; and Cochrane Library. From the search results, we estimated the significance of CRP level... The present meta-analysis included 12 studies, encompassing 2,204 patients. Based on combined data, an increased CRP level was significantly related to an unfavorable overall survival (OS) of patients... Based on the results of our present analyses, increased CRP levels were significant predictors of poor OS and PFS in patients with CC. CRP level, therefore, could be an independent and inexpensive fac... INPLASY, identifier INPLASY202360074....

Polymorphisms in FSHR modulating susceptibility to polycystic ovary syndrome: an updated meta-analysis.

Two polymorphisms, rs6165 and rs6166 located in the intracellular domain of FSHR has been reported to affect folliculogenesis, steroidogenesis and oocyte maturation. Several studies have highlighted t... A comprehensive literature search was made using PubMed, PCOSkb, and Google Scholar. New Ottawa Scale has been utilized to evaluate the quality of each article. To evaluate the strength of association... A total of 20 articles were selected for the present study. In pooled analysis and after the stratification by ethnicity, polymorphism rs6165 remains unrelated to the onset of PCOS. Besides, rs6166 ex... This meta-analysis suggests that GG genotype of rs6166 provides protection against PCOS, in a population-specific manner....

The prevalence of vancomycin-resistant Staphylococcus aureus in Ethiopia: a systematic review and meta-analysis.

Vancomycin-resistant Staphylococcus aureus, identified as a "high priority antibiotic-resistant pathogen" by the World Health Organization, poses a significant threat to human health. This systematic ... This systematic review and meta-analysis was reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Studies that reported VRSA prevalence due to... Of the 735 studies identified, 31 studies that fulfilled the eligibility criteria were included for meta-analysis consisted of 14,966 study participants and 2,348 S. aureus isolates. The overall poole... This study showed an alarmingly high pooled prevalence of VRSA necessitating routine screening, appropriate antibiotic usage, and robust infection prevention measures to manage MRSA infections and con... PROSPERO registration identification number: CRD42023422043....

Safety and Effectiveness of Sclerotherapy for Nonparasitic Splenic Cysts: A Systematic Review and Meta-Analysis.

To assess the reported safety and effectiveness of sclerotherapy for the treatment of nonparasitic splenic cysts through a systematic review and meta-analysis.... A systematic search of PubMed MEDLINE, Embase, Web of Science, and the Cochrane Library through July 2023 was performed. Studies including at least 5 patients reporting percutaneous sclerotherapy of n... Twenty-three of 833 citations were selected for full-text assessment, and 7 studies were included for a total of 99 patients. The methodological quality of the studies included scored 3-7. Composite a... Sclerotherapy of splenic cysts seemed to be safe, with a high rate of recurrence for cysts ≥8 cm....

Prognostic significance of STING expression in solid tumor: a systematic review and meta-analysis.

Stimulator of interferon genes (STING) is a key regulator in initiating innate immune response from sensing cytosolic DNA. Recent studies have revealed that the cGAS-STING signaling pathway has a cruc... Eleven studies including 2,345 patients were eligible for the analysis. STING expression in tumor cells was related to improved disease-free survival/recurrence-free survival (DFS/RFS) (HR = 0.656, 95... STING expression in tumor cells is associated with favorable outcome in solid tumors.... https://www.crd.york.ac.uk/prospero/, registration number: CRD42023427027....

Association of sleep duration and risk of mental disorder: a systematic review and meta-analysis.

The effects of sleep duration on the development of mental illness remain controversial. Therefore, it is necessary to identify the effects of long or short sleep duration on psychological disorders, ... Identifying published papers was accomplished by using the following five English databases on March 16, 2022: PubMed, MEDLINE, Embase, Web of Science databases, and Scopus. Cross-sectional and cohort... A total of 52 studies were included in this analysis, consisting of 14 cohort studies and 38 cross-sectional studies. These studies involved a combined sample size of 1,407,891 participants who met th... Short sleep duration, not long sleep duration, is an independent predictor of developing mental disorders, particularly anxiety and depression....

Impact of fear of recurrence in patients with cancer on caregivers' psychological health: A meta-analysis.

This study aims to quantitatively investigate the relationship between fear of cancer recurrence in patients with cancer and their caregivers' psychological health, examining the extent of the impact ... We conducted a comprehensive search in PubMed, EMBASE, Cochrane Library, Web of Science, CINAHL, and PsycINFO databases from inception until May 2023 for relevant English publications. Pearson correla... A total of 19 eligible studies were included in the analysis. The findings revealed a moderate positive correlation between fear of recurrence in patients with cancer and caregivers' fear of recurrenc... Our meta-analysis established a significant positive correlation between fear of recurrence in patients with cancer and negative psychological consequences among caregivers, including recurrence fear,... PROSPERO, CRD42022383866....

Neutrophil to Lymphocyte Ratio and Periprosthetic Joint Infection: A Systematic Review and Meta-Analysis.

The neutrophil-to-lymphocyte ratio (NLR) has shown promising results as a diagnostic tool for periprosthetic joint infection (PJI) after total joint arthroplasty. We conducted a systematic review and ... We searched PubMed, Scopus, and Web of Science from inception up to 2022 and evaluated the quality of the included literature.... Based on the 12 eligible studies, NLR levels were significantly higher in patients who had PJI compared to those who had aseptic loosening (standard mean difference (SMD) = 1.05, 95% Confidence Interv... In summary, this meta-analysis indicates that NLR is a reliable marker in the diagnosis of PJI....

A systematic review and meta-analysis of bovine brucellosis seroprevalence in Latin America and the Caribbean.

Bovine brucellosis is a significant public health problem in countries with economic and zoonotic implications. Although relevant, there are no previous systematic reviews about bovine brucellosis in ... We performed a systematic literature review in five data-bases to assess the seroprevalence of Brucella in cattle. A meta-analysis with a random-effects model was performed to calculate the pooled pre... The literature search yielded 3,403 articles, of which 65 studies were fully valid for analysis. The pooled seroprevalence for Brucella in bovine (n ​= ​46,883,177) was 4.0% (95%CI: 3.0%-5.0%; p ​< ​0... Some countries reported still relevant seroprevalences of bovine brucellosis, especially at the Central America and Caribbean islands. Multiple factors may influence the survival and spread of pathoge...

Association of serum lipids with inflammatory bowel disease: a systematic review and meta-analysis.

Serum lipid levels seem to be abnormal in Inflammatory bowel disease (IBD). However, the specific manifestation of abnormal serum lipid levels in IBD are heterogeneous among studies and have not been ... PubMed, EMBASE, and Cochrane Library databases were searched. Serum lipid levels were compared between IBD patients and Health individuals, Crohn's (CD) and ulcerative colitis (UC), active and inactiv... Overall, 53 studies were included. Compared with healthy controls, IBD patients had significantly lower TC (WMD = -0.506, 95%CI = -0.674 to -0.338,... The overall level of serum lipids in IBD patients is lower than that of healthy individuals and is negatively associated with disease severity.... https://www.crd.york.ac.uk/prospero/, identifier: CRD42022383885....